Small Cell Lung Cancer
Small Cell Lung Cancer
Advertisement
Cecilia BrownAdvancements in Oncology | June 16, 2024
Dr. Rami Manochakian and The Oncology Brothers discusses treatment for SCLC, which is evolving at a rapid pace.
Read More
David R. Spigel, MDASCO 2024: Focus on Lung Cancer | June 6, 2024
Dr. Spigel discusses the implications of ADRIATIC at the 2024 American Society of Clinical Oncology Annual Meeting.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 4, 2024
The median investigator-assessed PFS was 5.7 months in patients who received bevacizumab plus ACE.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 3, 2024
The ADRIATIC results were presented during a plenary session at the 2024 American Society of Clinical Oncology Meeting.
Cecilia BrownSmall Cell Lung Cancer | May 30, 2024
Researchers aimed to address the limited data on combining a PD-L1 inhibitor with chemotherapy in older adults.
Cecilia BrownLung Cancer | May 28, 2024
Exposures to substances such as Agent Orange are "not currently addressed in prevailing risk models."
Cecilia BrownSmall Cell Lung Cancer | May 20, 2024
The treatment is the first and only bispecific T-cell engager therapy for advanced SCLC.
Cecilia BrownSmall Cell Lung Cancer | May 17, 2024
Global clinical trials are scheduled to begin after IND approval is received for phase 2 trials in the US and Europe.
Cecilia BrownLung Cancer | May 15, 2024
The primary end point of the RESILIENT trial was OS.
Kaitlyn KoskoSmall Cell Lung Cancer | April 19, 2024
The timing of chemotherapy given to patients with SCLC does not have a statistically significant impact on OS.
Kaitlyn KoskoSmall Cell Lung Cancer | April 18, 2024
The timing of chemotherapy given to patients with SCLC does not have a statistically significant effect on OS.
Mary GreccoSmall Cell Lung Cancer | March 26, 2024
Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood.
Mary GreccoSmall Cell Lung Cancer | March 26, 2024
The DeLLphi-301 study that evaluated patients with advanced SCLC.
Mary GreccoSmall Cell Carcinoma | March 22, 2024
Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC.
Kaitlyn KoskoSmall Cell Lung Cancer | February 27, 2024
Researchers from the US and Italy have identified a biomarker that can distinguish between SCLC and SCC.
Kaitlyn KoskoSmall Cell Lung Cancer | January 25, 2024
Berzosertib plus topotecan significantly improves OS but not PFS in patients with relapsed small cell lung cancer.
Eileen Koutnik-FotopoulosSmall Cell Lung Cancer | December 27, 2023
A study analyzed the efficacy and safety of radiotherapy in patients with SCLC with brain metastases.
Kaitlyn KoskoSmall Cell Lung Cancer | December 26, 2023
Co-targeting neuroendocrine and non-NE cells may help reduce small cell lung cancer progression.
Mary GreccoWCLC 2023 | December 20, 2023
A study sought to ascertain the role of occupation in the risk of SCLC and adenocarcinoma in Spanish women.
Mary GreccoWCLC 2023 | December 19, 2023
The results of a study that aimed to subclassify SCLC based on certain immunoexpressions.
Advertisement
Advertisement
Advertisement
Latest News

June 19, 2024